ABSTRACT
Percutaneous transluminal aortic valvuloplasty (PTAV) is indicated for the patients with symptomatic severe aortic stenosis, who are contraindicated or very high risk for surgical valve replacement due to extremely advanced age, concomitant illness, and poor general condition.1,2 As the candidate patients tend to be physically debilitated and hemodynamically labile, a variety of adverse events can be anticipated during these procedures. In order to avoid potential PTAVrelated complications, it is critically important to perform a thorough evaluation of the baseline cardiac condition, to prepare for any potential adverse events in advance, and to pay meticulous care to details of technique based on a detailed understanding of the nature of this procedure.
